Cargando…

Current trends in drug metabolism and pharmacokinetics

Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the followin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuhua, Meng, Qiang, Yang, Mengbi, Liu, Dongyang, Hou, Xiangyu, Tang, Lan, Wang, Xin, Lyu, Yuanfeng, Chen, Xiaoyan, Liu, Kexin, Yu, Ai-Ming, Zuo, Zhong, Bi, Huichang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900561/
https://www.ncbi.nlm.nih.gov/pubmed/31867160
http://dx.doi.org/10.1016/j.apsb.2019.10.001
_version_ 1783477372996026368
author Li, Yuhua
Meng, Qiang
Yang, Mengbi
Liu, Dongyang
Hou, Xiangyu
Tang, Lan
Wang, Xin
Lyu, Yuanfeng
Chen, Xiaoyan
Liu, Kexin
Yu, Ai-Ming
Zuo, Zhong
Bi, Huichang
author_facet Li, Yuhua
Meng, Qiang
Yang, Mengbi
Liu, Dongyang
Hou, Xiangyu
Tang, Lan
Wang, Xin
Lyu, Yuanfeng
Chen, Xiaoyan
Liu, Kexin
Yu, Ai-Ming
Zuo, Zhong
Bi, Huichang
author_sort Li, Yuhua
collection PubMed
description Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the following aspects: (1) an update on drug-metabolizing enzymes and transporters in the determination of PK, as well as advances in xenobiotic receptors and noncoding RNAs (ncRNAs) in the modulation of PK, providing new understanding of the transcriptional and posttranscriptional regulatory mechanisms that result in inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drug–drug interactions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and microbiota-mediated interactions; (3) advances in understanding the effects of diseases on PK, particularly changes in metabolizing enzymes and transporters with disease progression; (4) trends in mathematical modeling including physiologically-based PK modeling and novel animal models such as CRISPR/Cas9-based animal models for DMPK studies; (5) emerging non-classical xenobiotic metabolic pathways and the involvement of novel metabolic enzymes, especially non-P450s. Existing challenges and perspectives on future directions are discussed, and may stimulate the development of new research models, technologies, and strategies towards the development of better drugs and improved clinical practice.
format Online
Article
Text
id pubmed-6900561
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69005612019-12-20 Current trends in drug metabolism and pharmacokinetics Li, Yuhua Meng, Qiang Yang, Mengbi Liu, Dongyang Hou, Xiangyu Tang, Lan Wang, Xin Lyu, Yuanfeng Chen, Xiaoyan Liu, Kexin Yu, Ai-Ming Zuo, Zhong Bi, Huichang Acta Pharm Sin B Review Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the following aspects: (1) an update on drug-metabolizing enzymes and transporters in the determination of PK, as well as advances in xenobiotic receptors and noncoding RNAs (ncRNAs) in the modulation of PK, providing new understanding of the transcriptional and posttranscriptional regulatory mechanisms that result in inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drug–drug interactions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and microbiota-mediated interactions; (3) advances in understanding the effects of diseases on PK, particularly changes in metabolizing enzymes and transporters with disease progression; (4) trends in mathematical modeling including physiologically-based PK modeling and novel animal models such as CRISPR/Cas9-based animal models for DMPK studies; (5) emerging non-classical xenobiotic metabolic pathways and the involvement of novel metabolic enzymes, especially non-P450s. Existing challenges and perspectives on future directions are discussed, and may stimulate the development of new research models, technologies, and strategies towards the development of better drugs and improved clinical practice. Elsevier 2019-11 2019-10-18 /pmc/articles/PMC6900561/ /pubmed/31867160 http://dx.doi.org/10.1016/j.apsb.2019.10.001 Text en © 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Li, Yuhua
Meng, Qiang
Yang, Mengbi
Liu, Dongyang
Hou, Xiangyu
Tang, Lan
Wang, Xin
Lyu, Yuanfeng
Chen, Xiaoyan
Liu, Kexin
Yu, Ai-Ming
Zuo, Zhong
Bi, Huichang
Current trends in drug metabolism and pharmacokinetics
title Current trends in drug metabolism and pharmacokinetics
title_full Current trends in drug metabolism and pharmacokinetics
title_fullStr Current trends in drug metabolism and pharmacokinetics
title_full_unstemmed Current trends in drug metabolism and pharmacokinetics
title_short Current trends in drug metabolism and pharmacokinetics
title_sort current trends in drug metabolism and pharmacokinetics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900561/
https://www.ncbi.nlm.nih.gov/pubmed/31867160
http://dx.doi.org/10.1016/j.apsb.2019.10.001
work_keys_str_mv AT liyuhua currenttrendsindrugmetabolismandpharmacokinetics
AT mengqiang currenttrendsindrugmetabolismandpharmacokinetics
AT yangmengbi currenttrendsindrugmetabolismandpharmacokinetics
AT liudongyang currenttrendsindrugmetabolismandpharmacokinetics
AT houxiangyu currenttrendsindrugmetabolismandpharmacokinetics
AT tanglan currenttrendsindrugmetabolismandpharmacokinetics
AT wangxin currenttrendsindrugmetabolismandpharmacokinetics
AT lyuyuanfeng currenttrendsindrugmetabolismandpharmacokinetics
AT chenxiaoyan currenttrendsindrugmetabolismandpharmacokinetics
AT liukexin currenttrendsindrugmetabolismandpharmacokinetics
AT yuaiming currenttrendsindrugmetabolismandpharmacokinetics
AT zuozhong currenttrendsindrugmetabolismandpharmacokinetics
AT bihuichang currenttrendsindrugmetabolismandpharmacokinetics